UNITE Study: Understanding New Interventions With GBM ThErapy

Summary

The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated with depatuxizumab mafodotin (ABT-414).

Timeline

Start

2018-07-30

Primary completion

2019-09-05

Completion

2020-03-03

Outcome

Outcome not reported

Stopped: “The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma was stopped due to lack of survival benefit.”

Drugs

Indications